Altabax (Retapamulin) Patent Expiration, LOE Window & CMS Spending

Altabax (Retapamulin) by Almirall: FDA Orange Book core substance LOE 2027-02-14, 0 AB generics, $20K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAlmirall
FDA Application & PathwayN022055 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2027-02-14
Last Listed Patent or Exclusivity Date2027-02-14
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$20K
2024 Medicare Part D Spend$20K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel